WO2004069833A1 - 縮環ピリジン誘導体、その製造法および用途 - Google Patents
縮環ピリジン誘導体、その製造法および用途 Download PDFInfo
- Publication number
- WO2004069833A1 WO2004069833A1 PCT/JP2004/001169 JP2004001169W WO2004069833A1 WO 2004069833 A1 WO2004069833 A1 WO 2004069833A1 JP 2004001169 W JP2004001169 W JP 2004001169W WO 2004069833 A1 WO2004069833 A1 WO 2004069833A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- group
- substituted
- alkyl
- atom
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- HIV human immunodeficiency virus
- protease inhibitors have been developed as a treatment for AIDS (acquired immunodeficiency syndrome) and can be combined with two previously used HIV reverse transcriptase inhibitors.
- AIDS immunodeficiency syndrome
- -CD4 has long been known as a receptor for HIV entry into target cells, but recently as a second receptor for macrophage-directed HIV, CCR5 and T cell-directed second receptor.
- Patent Document 2 Japanese Patent Application No. 10-234388
- Patent Document 3 Japanese Patent Application No. 10-36 3404
- Patent Document 4 Japanese Patent Application Laid-Open No. 200-012686 Disclosure of the Invention
- the present invention provides a novel bicyclic compound that is useful as a prophylactic / therapeutic agent for HIV infection, particularly AIDS, based on CCR antagonistic activity, particularly CCR5 antagonistic activity.
- R 1 is optionally substituted with benzene, furan, thiophene, .pyridin, cyclopentane, cyclohexane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine or tetrahydropyran
- benzene furan, thiophene, .pyridin, cyclopentane, cyclohexane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine or tetrahydropyran
- R 2 is (1) an amino group in which a nitrogen atom may be substituted and a nitrogen atom may be quaternized or oxidized; (2) an amino group which may be substituted and is a ring-constituting atom. A nitrogen-containing heterocyclic group in which a nitrogen atom may be quaternary ammonified or oxidized; (3) an optionally substituted amidino group or (4 ) A compound according to the above (1), which is a guanidino group which may be substituted;
- R 2 is represented by the formula: NRR '(R and R, each represents an optionally substituted aliphatic hydrocarbon group or an optionally substituted alicyclic heterocyclic group) A compound according to (1) above,
- C i _ 4 represents an optionally imino group or a bond optionally substituted with an alkyl group
- W 1 is C i as a bond or each substituent - 6 alkyl, hydroxyl , hydroxy i amino, C - 4 alkenylene chain
- R 2 is C i - - 6 Arukokishiimino have good d _ 4 even if ⁇ alkylene chain or C 2 4 alkyl group may be substituted, amino
- the compound according to the above (1) which is a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as a group or a ring-constituting atom, and is optionally substituted with a C 4 alkyl group.
- n ' is 1, 2 or 3
- na is 0 or 1
- Z 2 a is bond
- S indicates the SO or S_ ⁇ 2, and other symbols are as defined above.
- Y a is formyl as a substituent, may be substituted - 6 alkyl, which may be substitution C ⁇ - 6 alkenyl, optionally substituted Ariru, heterocyclic ring which may be substituted
- a 6-membered aromatic hydrocarbon such as benzene, cyclopentane 5- or 6-membered aliphatic hydrocarbons such as cyclohexane, cyclopentene, cyclohexene, cyclopentane, cyclohexanegen, furan, thiophene, pyrroyl, imidazole, pyrazol, and thiazol.
- One or two heteroatoms selected from nitrogen, sulfur, and oxygen such as oxazole, isothiazole, isoxazole, tetrazol, pyridine, pyrazine, pyrimidine, pyridazine, and triazole.
- One or two heteroatoms selected from nitrogen, sulfur and oxygen such as oxazine, oxazineazine, thiazine, thiadiazine, morpholine, thiomorpholine, pyran, tetrahydropyran and tetrahydrothiopyran.
- Examples include groups formed by removing one hydrogen atom from the contained 5- or 6-membered non-aromatic heterocycle and the like.
- the "5- or 6-membered ring" includes benzene, furan, and thiophene.
- alkyl in the alkyl which may be substituted as the substituent for R 1 examples include linear or branched alkyl having 1 to 10 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and the like.
- substituent in the optionally substituted alkyl include halogen (eg, fluorine, chlorine, bromine, iodine, etc.), nitro, cyano, hydroxyl, and optionally substituted thiol (eg, thiol, C! _ 4 alkylthio, etc.) Amino group which may be substituted
- Ci-4 alkoxyl C! _ 4 alkoxy e.g., Metokishime butoxy, Metokishetokishi, ethoxyethoxy, triflumizole Ruo b methoxy E butoxy, Bok Riffle O b ethoxy E Bok carboxymethyl, etc.
- formyl C 2 one 4 Arukanoiru (eg, Asechi Le, propionyl, etc.)
- C x _ 4 alkylsulfonyl eg, methanesulfonyl, ethanesulfonyl, etc.
- the number of substituents is preferably 1 to 3.
- the cycloalkyl Le in which may cycloalkyl substituted as the substituent of R 1, for example, cyclopropyl, cyclobutyl, cyclopentyl, key sill cyclohexane, C 3, such as heptyl cyclohexane - such as cycloalkyl and the like .
- Said replaced Examples of the substituent in the optionally substituted cycloalkyl include halogen (eg, fluorine, chlorine, bromine, iodine, etc.), nitro, cyano, hydroxyl, and optionally substituted thiol.
- an optionally substituted amino group e.g., Amino, mono C i - 4 Arukiruamino, di C i - 4 alkylamino, Tetorahidoropi roll, piperidines Rajin, piperidine , morpholine, thiomorpholine, pyrosulfate Ichiru, such as 5 or 6 membered cyclic Amino, such as imidazole), esterified or amidated which may be force Rupokishiru group (eg, Karupokishiru, CJ _ 4 alkoxy force Ruponiru, Cal Pamoiru, mono CJ _ 4 alkyl force Rubamoiru, di.
- Rupokishiru group eg, Karupokishiru, CJ _ 4 alkoxy force Ruponiru, Cal Pamoiru, mono CJ _ 4 alkyl force Rubamoiru, di.
- halogenated which may be C i one 4 alkoxy (e.g., main Bok carboxymethyl, ethoxy, flop Robokishi, butoxy, triflumizole Ruo b methoxy , Trifluoroethoxy, etc.), and halogenated C i- 4 alkoxy-1 C!
- alkoxy e.g., methoxy methoxyethanol, methoxyethoxy, E WINCH Kishe Bok alkoxy, triflate Ruo b methoxy E butoxy, triflumizole Ruo b ethoxyethoxy, etc.
- formyl C 2 - 4 Arukanoiru (eg, Asechiru, propionyl, etc.), d- 4 alkylsulfonyl (eg, methanesulfonyl, ethanesulfonyl, and the like); and the number of substituents is preferably 1 to 3.
- substituent in the optionally substituted hydroxyl group as a substituent of R 1 include (1) optionally substituted alkyl (for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert. !.-butyl, pentyl, Isopen hexyl chill, neopentyl, to, heptyl, Okuchiru, Noel, C one 1 alkyl such as decyl, preferably like lower alkyl) (C one 6!);
- optionally substituted alkyl for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert. !.-butyl, pentyl, Isopen hexyl chill, neopentyl, to, heptyl, Okuchiru, Noel, C one 1 alkyl such as
- (2) may be substituted, if example good cycloalkyl (eg optionally containing heteroatoms, C 3 cyclopropyl, cyclobutyl, cyclopentyl, to consequent opening cyclohexyl, cyclohexylene, etc.
- good cycloalkyl eg optionally containing heteroatoms, C 3 cyclopropyl, cyclobutyl, cyclopentyl, to consequent opening cyclohexyl, cyclohexylene, etc.
- cycloheptyl - 7 cycloalkyl tetrahydrofuranyl Saturated 5- or 6-membered heterocycles containing one or two heteroatoms, such as nil, tetrahydrophenyl, pyrrolidinyl, virazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydroviranyl, tetrahydrothiopyrael, etc. Group (preferably tetrahi Doroviranil, etc.); and the like);
- alkenyl e.g., Ariru (al lyl), crotyl, 2-base Nparu, C 2 -C such cyclohexenyl 3- to 1 0 Arukeniru, preferably lower (C 2 - 6) alkenyl Etc.
- cycloalkenyl which may be substituted (for example, cycloalkenyl having 3 to 7 carbon atoms such as 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl, etc.) );
- optionally substituted aralkyl for example, phenyl C! 1-4 alkyl (eg, benzyl, phenethyl, etc.) and the like);
- acyl for example, C 2 -C 4 alkanoyl (eg, acetyl, propionyl, butyryl, isoptyryl, etc.), C 1 -C 4 alkylsulfonyl (eg, methanesulfonyl, Ethanesulfonyl and the like));
- C 2 -C 4 alkanoyl eg, acetyl, propionyl, butyryl, isoptyryl, etc.
- C 1 -C 4 alkylsulfonyl eg, methanesulfonyl, Ethanesulfonyl and the like
- substituents such as aryl which may be substituted (for example, phenyl, naphthyl, etc.);
- optionally substituted alkyl, (2) optionally substituted cycloalkyl, (3) optionally substituted alkenyl, (4) optionally substituted cycloalkenyl, ( 5) optionally substituted aralkyl, (6) optionally substituted aryl, and (7) optionally substituted aryl may include halogen (for example, fluorine, chlorine, bromine, iodine), nitro -, Shiano, hydroxyl, optionally substituted thiol group (e.g., thiol, C _ 4 alkylthio, etc.), an optionally substituted amino group ( examples, Amino, mono C i - 4 Arukiruamino, di C i _ 4 Arukiruamino, tetrahydrophthalic pyro Ichiru, piperidines Rajin, piperidine, mol holin, thiomorpholine, pyrrole, such as imidazole A 5- or 6-membered
- Alkylsulfonyl eg, methanesulfonyl, ethanesulfonyl, etc.
- optionally substituted 5- or 6-membered aromatic heterocycle eg, furan, thiophene, pyrrol, imidazole, pyrazole, thiazole, oxazole,
- cycloalkyl e.g., cyclopropyl, Shikuropuchi Le, cyclopentyl, cyclohexyl, C 3, such as heptyl cyclohexane - such as 7 cycloalkyl Le and the like;
- aralkyl eg, phenyl—C! 1-4 alkyl
- C i one optionally 4 alkoxy one CJ _ 4 alkoxy (e.g., methoxymethoxy, Metokishe Bok alkoxy, Etokishetokishi, Bok Rifuruoro Metokishetokishi and triflic O b ethoxyethoxy), formyl, C 2 one 4 Arukanoiru (eg, Asechiru, etc. flop port Pioniru), CJ _ 4 alkylsulfonyl (e.g., methanesulfonyl, etc. Etansu Ruhoniru) and the like,
- the number of substituents is preferably 1 to 3.
- substitution Alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.
- alkyl preferably lower (CJ_6) alkyl and the like
- cycloalkyl e.g., cyclopropyl, Shikuropuchi Le, cyclopentyl, cyclohexyl, etc. C 3 one 7 cycloalkyl Le such heptyl cyclohexane and the like;
- alkenyl for example, alkenyl having 2 to 10 carbon atoms such as allyl, crotyl, 2-pentenyl, 3-hexenyl, preferably lower (
- cycloalkenyl which may be substituted (for example, cycloalkenyl having 3 to 7 carbon atoms such as 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl, etc.) Etc.); '
- acyl e.g., alkanoyl having 2 to 4 carbons (e.g., acetyl, propionyl, butyryl, isobutyryl, etc.), an alkylsulfonyl having 1 to 4 carbons (e.g., methanesulfonyl, Ethanesulfonyl and the like));
- alkanoyl having 2 to 4 carbons e.g., acetyl, propionyl, butyryl, isobutyryl, etc.
- alkylsulfonyl having 1 to 4 carbons e.g., methanesulfonyl, Ethanesulfonyl and the like
- aryls which may be substituted (for example, phenyl, naphthyl, etc.), and the like.
- optionally substituted alkyl (2) optionally substituted cycloalkyl, (3) optionally substituted alkenyl, (4) optionally substituted cycloalkenyl, ( 5)
- the optionally substituted acyl group and (6) the optionally substituted aryl group may be halogen (eg, fluorine, chlorine)
- Optionally halogenated C i- 4 alkoxy eg, methoxy, ethoxy, propyloxy, butoxy, trifluoromethoxy, trifluoroethoxy, etc.
- optionally halogenated C i one 4 alkoxy one C! _ 4 alkoxy e.g., methoxy methoxyethanol, methoxyethoxy, ethoxyethoxy, triflumizole Ruo b methoxy E butoxy, etc. triflate Ruo b ethoxyethoxy
- the amino group which may be substituted as a substituent of R 1 is a cyclic amino group (for example, tetrahydropyrrole, piperazine, piperidine, It is formed by removing one hydrogen atom from a nitrogen atom constituting a 5- or 6-membered ring such as morpholine, thiomorpholine, pyrrole, imidazole, etc., and forms a cyclic amino group having a bond on the nitrogen atom. May be.
- the cyclic amino group may have a substituent.
- substituents include halogen (eg, fluorine, chlorine, bromine, iodine, etc.), nitro, cyano, hydroxyl, and optionally substituted thiol.
- halogen eg, fluorine, chlorine, bromine, iodine, etc.
- nitro cyano
- hydroxyl e.g., hydroxyl
- optionally substituted thiol e.g, thiol, C
- Examples of the optionally substituted acyl group for R 1 include:
- Alkyl which may be substituted e.g., methyl, ethyl, propyl, isopyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, C ⁇ -i such as decyl, preferably alkyl (preferably lower (C i- 6 ) alkyl);
- alkenyl which may be substituted (for example, alkenyl having 2 to 10 carbon atoms, such as allyl, crotyl, 2-pentenyl and 3-hexenyl, preferably lower (
- Examples of the optionally esterified carbonyl group as a substituent of R 1 include (1) hydrogen,
- Alkyl which may be substituted for example, methyl, ethyl, propyl, isopyl, butyl, isoptyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl
- Alkyl preferably lower (C i - 6) such as an alkyl and the like); (3) optionally substituted cycloalkyl (e.g., cyclopropyl, Shikuropuchi Le, C, such as heptyl cyclopentyl, cyclohexylene cyclohexyl, cyclohexylene such as 3 _ 7 cycloalkyl Le and the like);
- cycloalkyl e.g., cyclopropyl, Shikuropuchi Le, C, such as heptyl cyclopentyl, cyclohexylene cyclohexyl, cyclohexylene such as 3 _ 7 cycloalkyl Le and the like
- alkenyl e.g., Ariru (al lyl), crotyl, 2 one base Nparu, 3 C 2 -C such as single-hexenyl and 1 0 of Arukeniru, preferably lower (C 2 - 6) alkenyl And the like);
- cycloalkenyl for example, cycloalkenyl having 3 to 7 carbon atoms such as 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl, etc.
- aryl eg, phenyl, naphthyl, etc.
- a carbonyl group preferably carboxyl, lower (CC- 6 ) alkoxycarbonyl, aryloxy carbonyl
- Examples include methoxycarbonyl, ethoxyl-ponyl, propoxyl-lponyl, phenoxyl-lponyl, naphthoxyl-carbonyl, etc., and the above-mentioned (2) optionally substituted alkyl, (3) optionally substituted cyclo Alkyl, (4) optionally substituted alkenyl, (5) optionally substituted cycloalkenyl, and (6) optionally substituted substituents of the optionally substituted aryl Halogen (eg, fluorine, chlorine, bromine, iodine, etc.), nitro, cyano, hydroxyl, substituted Good thiol group (e.g., thiol, C! _ 4 alkylthio, etc
- C i one 4 may be halogenated Alkoxy (eg, methoxy, ethoxy, propoxy, buto Xy, trifluoromethoxy, trifluoroethoxy, etc.), which may be halogenated C!
- C - 4 alkoxy one C - 4 alkoxy (e.g., methoxymethoxy, Metokishe butoxy, ethoxyethoxy, triflumizole Ruo b methoxy E butoxy, triflumizole Ruo b ethoxyethoxy, etc.), formyl, C 2 _ 4 Arukanoiru (eg, Asechiru, etc. propionyl ), C! _ 4 alkylsulfonyl (eg, methanesulfonyl, ethanesulfonyl, etc.) and the like, and the number of substituents is preferably 1 to 3.
- Examples of the aromatic group in the aromatic group which may be substituted as the substituent for R 1 include phenyl, pyridyl, furyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, tetrazolyl, and pyrazinyl.
- halogen e.g., fluorine, chlorine, bromine, iodine
- nitro Shiano, hydroxyl, Yoi thiol group which may be substituted (e.g., thiol, C i _ 4 alkylthio
- substituted amino groups eg, amino, mono- 4- alkylamino, di-dialkyl- 4- alkylamino, tetrahydropyrrole, piperazine, piperidine, morpholine, thiomorpholine
- a 5- or 6-membered cyclic amino such as pyrrol, imidazole, etc.
- an esterified or amidated olepoxyl group eg, carboxyl, C i- 4 alkoxycarbonyl, olebamoyl, mono _ 4 alkyl force Rubamoiru, such as di _ 4 alkylcarbamoyl
- optionally halogenated C i - 4 alkyl e.g., triflate Ruoromechiru, methyl, etc.
- C i _ 4 optionally halogenated C i _ 4 even though alkoxy (e.g., methoxy, ethoxy, Purobokishi, butoxy, Torifuruorome Bok alkoxy, preparative Riffle O b ethoxy, etc.), formyl, C 2 _ 4 Arukanoiru (eg, Asechiru, pro Pioniru etc.), - 4 alkylsulfonyl (e.g., Metansuruhoyuru, Etansuru And the like, and the number of substituents is preferably 1 to 3.
- alkoxy e.g., methoxy, ethoxy, Purobokishi, butoxy, Torifuruorome Bok alkoxy, preparative Riffle O b ethoxy, etc.
- formyl e.g., Asechiru, pro Pioniru etc.
- - 4 alkylsulfonyl e.g., Metan
- R 1 substituents may be the same or different and may be substituted at any position of the ring.
- the “5- or 6-membered ring” of the “optionally substituted 5- or 6-membered ring” represented by R 1 has two or more substituents, two of these substituents bonded to, for example, lower (Ci _ 6) alkylene (e.g., trimethylene, tetramethylene, etc.), lower (C _ 6!) Arukirenoki sheet (e.g., -CH 2 -.
- Examples of the lower alkyl group of the “optionally substituted lower alkyl group” for R 3 include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert one-butyl, pentyl, Isopenchiru, neopentyl, etc.
- C i _ 6 alkyl such as key sill and the like to.
- cycloalkenyl for example, cycloalkenyl having 3 to 7 carbon atoms such as 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl and the like;
- cycloalkyl primary alkyl (!. E.g., cyclopropylmethyl, Shikuropuchirume chill, cyclopentylmethyl, cyclohexylmethyl cyclohexane, C 3, such as Puchirumechiru cyclohexane - 7 cycloalkyl - C - 4 alkyl and the like);
- substituent be halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, Shiano, hydroxyl, optionally substituted thiols groups (e.g., thiols, C -! 4 alkylthio, etc.) , optionally substituted amino group (e.g., amino, mono C i -!
- Imidazo such 5 or 6 membered cyclic Amino, such Ichiru
- esterified or amidated carboxyl group which may be (e.g., Karupokishiru, CJ _ 4 alkoxy force Lupo two Le, force Rubamoiru, mono C i one, alkyl force Rubamoiru, di ⁇ 1 one ⁇ alkyl carba mode ),
- halogenated C ⁇ -4 alkyl eg, trifluoromethyl, methyl, ethyl, etc.
- optionally halogenated Ci- 4 alkoxy eg, methoxy, ethoxy, Proboxy, butoxy, trifluoromethoxy, trifluoroethoxy, etc.
- heterocyclic group in the “optionally substituted heterocyclic group” and the “optionally substituted heterocyclic group” for R 4 , an aromatic heterocyclic ring or a non-aromatic heterocyclic ring And a group formed by removing one hydrogen atom.
- aromatic heterocycle examples include furan, thiophene, pyrrol, imidazole, pyrazole, thiazol, oxazole, isotiazole, isoxazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, 'triazol, And 5- or 6-membered aromatic heterocycles containing 1 to 4 heteroatoms selected from nitrogen, sulfur and oxygen, such as oxaziazol and thiadiazole.
- R 4 which may be halogenated or hydroxide C i -. 4 alkyl, formyl, halogenated or optionally hydroxylated C 2 _ 5 Arukanoiru such further favorable preferred, especially, propyl , Isobutyl, isobutenyl or 3-hydroxy-l-methylpropyl are preferred.
- Another preferred embodiment of R 4 is a compound represented by the formula-(CH 2 ) s
- n is preferably 1 or 2, and particularly preferably 2.
- the “optionally substituted 5- or 6-membered aromatic ring” represented by Z 1 may be a 6-membered aromatic hydrocarbon such as benzene, furan, thiophene, pyrrole, imidazole or the like.
- Alkyl groups eg, methyl, ethyl, trifluoromethyl, trifluoroethyl, etc.
- Ci- 4 alkoxy groups which may be substituted with halogen atoms (eg, methoxy, ethoxy, propoxy) , Trifluoromethoxy, trifluoroethoxy, etc.), but preferably have no substituents other than X 2 and Z 2 , and Z 1 is a 6-membered ring (preferably benzene).
- the substitution position of Z 2 is the para position of X 2 It is preferable that
- the 1 substituents are as Z 1) a halogen atom, 2) halo gen atoms optionally substituted C i _ 4 alkyl group or 3) halogen atoms substituted by optionally may be Ci one 4 alkoxy group Benzene which may have a methyl group or a trifluoromethyl group as a substituent is particularly preferable.
- Alkyl eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl
- alkylene chain of the “optionally substituted alkylene group” represented by W 1 and W 2 for example, one (CH 2 ) k ! -(k 1 is an integer of 1 to 4).
- Alkenylene chain represented by the following formula:
- Arukokishiimino group and the like preferably lower alkyl (preferably of 1 -C 6, C! _ 3 alkyl), hydroxyl, Okiso, hydrate port Kishiimino group, (hydroxyl group, Shiano group , esterified or amidated good force
- Rupokishiru group optionally (eg, Karupokishiru, C! _ 4 alkoxy Shi force Ruponiru force Rubamoiru, mono C ⁇ 4 alkyl force Rubamoiru, such as C!
- One 4 alkyl force may be substituted with polar groups, such as) such Rubamoiru) a lower (C! _ 6)
- Examples of the phosphono group which may be esterified include P ( ⁇ ) (OR 7 ) (OR 8 ) wherein R 7 and R 8 are each hydrogen, an alkyl group having 1 to 6 carbon atoms or a carbon atom having 3 carbon atoms. And R 7 and R 8 may be combined with each other to form a 5- to 7-membered ring].
- alkyl group having 1 to 6 carbon atoms represented by R 7 and R 8 methyl, ethyl, propyl, isopropyl, butyl, isoptyl, sec-butyl, tert-butyl, pentyl-, isopentyl, neopentyl
- cycloalkyl having 3 to 7 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, preferably a chain having 1 to 7 carbon atoms.
- lower alkyl having 6 carbon atoms more preferably lower alkyl having 1 to 3 carbon atoms.
- Examples of the amide of the amide group of the amide group which may be amidated include a carbonyl group and an alkylamino group having 1 to 6 carbon atoms, a cycloalkylamino group having 3 to 7 carbon atoms, or a 5- to 8-membered cyclic amine ( examples include pyrrolidine, piperidine, those morpholine, etc.) and is bonded, for example the force Rubamoiru, mono C ⁇ _ 6 alkyl force Rubamoiru, di-C
- Z 2a represents a bond, S, SO or SO 2 , and among them, SO is preferable, and in this case, the configuration of SO is preferably (S).
- Bonding position of Z 2 in Z 1 in the case of Z 1 is a benzene ring, bur yo any position, but is preferably in the para position.
- the “amino group which may be substituted and in which a nitrogen atom may be quaternary ammodimed or oxidized” represented by R 2 is one or two Examples include an amino group which may have a substituent, an amino group having three substituents and a quaternary ammonium nitrogen atom, and the like.
- the counter-anion of an amino group in which a nitrogen atom has been quaternized into ammonia may be a halogen atom anion (eg, C 1-, Br 1, I, etc.)
- anions derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, Cuic acid, succinic acid, malic acid, me
- cycloalkyl e.g., cyclopropyl, Shikuropuchi Le, cyclopentyl, cyclohexyl, cycloheptyl cyclohexane, C 3, such as Shianookuchiru - 8, such as cycloalkyl and the like;
- the cycloalkyl contains one heteroatom selected from a sulfur atom, an oxygen atom and a nitrogen atom, and is composed of oxysilane, thiolane, aziridine, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, tetrahydropyran, and tetrahydrothiovira.
- Tetrahydrothiopyran 1-oxide, piperidine and the like (preferably a 6-membered tetrahydropyran, tetrahydrothiopyran, piperidine and the like) may be formed, and the bonding position with the amino group is 3 or 4.
- the cycloalkyl is condensed with a benzene ring to form an indane (eg, indane-11-yl, indane-12-yl, etc.), Tetrahydronaphthalene (e.g., tetrahydronaphthalene-1-yl, tetrahydronaphthalene-1-6-yl (Preferably, indian, etc.);
- the cycloalkyl is cross-linked via a linear atom chain having 1 or 2 carbon atoms to form bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, Bicyclo [3.2.1] octyl, bicyclo [3.2.2] noel, and the like (preferably, cyclohexyl having a bridge through a linear atom chain having 1 or 2 carbon atoms, such as Preferably, it may form a bridged cyclic hydrocarbon residue such as bicyclo [2.2.1] heptyl).
- alkenyl which may be substituted (e.g., Ariru (allyl), crotyl, 2-Bae Nparu, C 2 -C such cyclohexenyl 3- to 1 0 Arukeniru, preferably lower (C 2 - 6) alkenyl, etc. Is increased);
- cycloalkenyl which may be substituted (for example, cycloalkenyl having 3 to 7 carbon atoms such as 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl, etc.) );
- Ararukiru e.g., Hue: Le - d _ 4 alkyl (e.g. , Benzyl, phenethyl and the like)
- acyl e.g., alkanol having 2 to 4 carbon atoms (e.g., acetyl, propionyl, butyryl, isoptyryl, etc.), alkylsulfonyl having 1 to 4 carbon atoms (e.g., methanesulfonyl, Ethanesulfonyl, etc.), C1-C4 alkoxycarbonyl (eg, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), C7-C10 aralkyloxycarbonyl (eg, benzyloxycarbonyl, etc.) And the like);
- alkanol having 2 to 4 carbon atoms e.g., acetyl, propionyl, butyryl, isoptyryl, etc.
- alkylsulfonyl having 1 to 4 carbon atoms e.g., methanesulfonyl, Ethanes
- optionally substituted aryl eg, phenyl, naphthyl, etc.
- Heterocyclic group which may be substituted for example, furan, thiophene, pyrrol, imidazole, pyrazole, thiazole, oxazole, isothiazole, isoxazol
- substituents also, eight androgenic (e.g., fluorine, chlorine, bromine, iodine, etc.), which may lower halogenated (CJ _ 4) alkyl, hydroxyl group, Shiano group, esterified or amidated are optionally substituted by a polar group such which may carboxyl group optionally substituted lower (C E _ 4) alkyl (e.g., hydroxy C E - 4 alkyl Le, Shiano C ⁇ one 4 alkyl, force Rupokishiru C _ 4 alkyl , C i — 4- Alkoxy Power Luponyl — 4 Alkyl, Power Lubamoyl _ 4 Alkyl, Mono C i — 4 Alkyl Power Lubamoyl ⁇ — 4 Alkyl, Di C i — 4 Alkyl Power Lubamoyl, Di C i — 4 Alkyl Power Lubamoyl E _ 4 alkyl, pyrrolidino force Lupo sul
- R 2 may be substituted, may contain a sulfur atom or an oxygen atom as a ring-constituting atom, and may have a nitrogen atom quaternary ammonium or oxidized.
- R 2 may be substituted, may contain a sulfur atom or an oxygen atom as a ring-constituting atom, and may have a nitrogen atom quaternary ammonium or oxidized.
- the nitrogen-containing heterocyclic group which may be
- anions derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid
- Anions derived from organic acids such as fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, P-toluenesulfonic acid, aspartic acid, dartami
- acids derived from acidic amino acids such as acid, and among them, C 11, Br—, and I— are preferred.
- the “nitrogen-containing heterocyclic group” may be bonded to the divalent group represented by Z 2 through either a carbon atom or a nitrogen atom, and may be 2-pyridyl, 3-pyridyl, 2-piperidinyl, etc. May be bonded on the ring-constituting carbon atom as in
- an optionally substituted amino group e.g., amino, mono C i 4 Arukiruamino, di C i 4 Arukiruamino, Te tiger hydro pyrrole, piperidines Rajin, piperidine, morpholine, thiomorpholine, pyrosulfate Lumpur, such as 5 or 6 membered cyclic Amino, such as imidazole) Esterification or Ami De of which may be force Rupokishiru group (eg, Karupokishiru, C _ 4 Arukokishikaru Poniru force Rubamoiru, mono d _ 4 alkyl force Rubamoiru, di ⁇ E - 4 such as an alkyl Cal Bamoiru), a lower (C i _ 4 ) alkoxy - power Ruponiru, formyl, lower (C 2 one 4) Arukanoiru, lower (C i - 4) alkylsulf
- Alkylsulfonyl eg, methanesulfonyl, ethanesulfonyl, etc.
- CJ _ 3 alkylenedioxy eg, methylenedioxy, ethylenedioxy, etc.
- cyano nitro, hydroxyl group
- thiol group which may be substituted (eg, thiol, C i _ 4 alkyl thio, etc.)
- an optionally substituted amino group e.g., amino, mono - alkyl amino, di C i - 4 Arukiruamino, tetrahydrophthalic pyro Ichiru, piperidines Rajin, Piberiji down, morpholine, thiomorpholine , pyromellitic Ichiru, such as 5 or 6-membered ring-like amino such as imidazole
- good force Rupokishiru group eg be esterified or amidated, carboxyl, C!
- a nitrogen-containing complex which may be substituted may contain a sulfur atom or an oxygen atom as a ring-constituting atom, and may have a nitrogen atom which may be quaternized or oxidized.
- the substituent which the “nitrogen-containing heterocyclic ring” of the “ring group” may have is , (1) halogen, (2) cyano, (3) hydroxyl group, (4) lipoxyl group, (5) rubamoyl group, (6) lower (Ci- 4 ) alkoxy- propylonyl, (7) lower
- Alkyl which may be substituted e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, C such as decyl
- alkyl preferably lower (CJ _ 6) such as an alkyl and the like);
- optionally substituted cycloalkyl e.g., cyclopropyl, Shikuropuchi Le, C, such as heptyl cyclopentyl, cyclohexylene cyclohexyl, cyclohexylene 3 such as a single 7 cycloalkyl Le and the like);
- alkenyl e.g., Ariru (allyl), crotyl, 2-base Nparu, C 2 -C such cyclohexenyl 3- to 1 0 Arukeniru, preferably lower (C 2 - 6) alkenyl Etc.
- cycloalkenyl eg, 2-cyclopentenyl, 2 3-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl, and the like, and cycloalkenyl having 3 to 7 carbon atoms
- alkynyl which may be substituted (for example, alkynyl having 2 to 10 carbon atoms such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-pentynyl and 3-hexynyl, preferably lower ( C 2 — 6 ) alkynyl and the like);
- Ararukiru e.g., phenylene Lou C i - 4 alkyl (e.g., benzyl, phenethyl) and the like);
- optionally substituted aryl for example, phenyl, naphthyl, etc. and the like; (1) optionally substituted alkyl, (2) optionally substituted Cycloalkyl, (3) optionally substituted alkenyl, (4) optionally substituted cycloalkenyl, (5) optionally substituted alkynyl, (6) optionally substituted aralkyl, and (7)
- substituent which the aryl which may be substituted may have include halogen (eg, fluorine, chlorine, bromine, iodine, etc.), nitro, cyano, hydroxyl, and optionally substituted thiol. group (e.g., thiol, C! _ 4 alkylthio, etc.), an optionally substituted amino group (e.g., amino, mono C
- C i may be halogenated - 4 alkyl (eg, triflate Ruo Russia, methyl, etc. Echiru)
- C i _ 4 alkoxy which may be halogenated (eg, main Bok carboxymethyl, ethoxy, tri Furuorometokishi, triflumizole Ruo Roe setter sheet, etc.)
- formyl C 2 _ 4 Alkanol
- the “optionally substituted hydroxyl group” represented by R 5 and R 6 includes, for example, (1) optionally substituted alkyl (eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec— butyl, tert- butyl, pentyl, Isobe pentyl, neopentyl, hexyl, heptyl, Okuchiru, nonyl, Ci one alpha 0 alkyl and decyl, preferably lower (! C _ 6) such as an alkyl and the like);
- optionally substituted alkyl eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec— butyl, tert- butyl, pentyl, Isobe pentyl, neopentyl, hexyl, heptyl, Okuchiru, nonyl
- cycloalkyl e.g., cyclopropyl, Shikuropuchi Le, cyclopentyl, cyclohexyl, etc.
- C 3 one 7 cycloalkyl Le such heptyl to consequent opening are mentioned cyclohexylene
- alkenyl which may be substituted for example, alkenyl having 2 to 10 carbon atoms such as allyl, crotyl, 2-pentenyl, 3-hexenyl, preferably lower
- cycloalkenyl which may be substituted (for example, cycloalkenyl having 3 to 7 carbon atoms such as 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl, etc.) );
- Ararukiru e.g., phenyl - C ⁇ - 4 alkyl
- Formyl or an optionally substituted acyl for example, alkanoyl having 2 to 4 carbon atoms (eg, acetyl, propionyl, butyryl, isobutyryl, etc.), carbon number
- R 5 and R 6 may be bonded to each other to form a cyclic group (preferably a 5- to 7-membered ring) together with an adjacent phosphorus atom.
- a cyclic group may have a substituent.
- the substituent include a halogen (eg, fluorine, chlorine, bromine, iodine, etc.), nitro, cyano, hydroxyl, and optionally substituted thiol group. (eg. Chio Le, such as C! one 4 alkylthio), an optionally substituted amino group (e.g., amino, motor yc! _ 4 alkylamino, di c 4 alkylamino .. tetrahydropyrrole, piperazinyl Rajin, Piperidine, morpholine .. thiomorpholine, pyrrole, imidazole, etc.
- a halogen eg, fluorine, chlorine, bromine, iodine, etc.
- Pokishiru group e.g., carboxyl, C! _ 4 alkoxy force Ruponiru force Rubamoiru, mode C!
- Ci- 4 alkyl e.g., trifluoromethyl, methyl, ethyl, etc.
- Ci- 4 alkoxy eg, methoxy, ethoxy, triflumizole Ruo b methoxy, triflumizole Ruo b ethoxy, etc.
- formyl C 2 _ 4 alkanol I le (eg, Asechiru, propionyl, etc.)
- C Bok 4 alkylsulfonyl e.g., meta Nsuruhoniru, etc. ethanesulfonyl
- the number of substituents, three one-stone is preferred.
- the counter and anion may be a halogen atom anion (eg, CI—, Br—, I—, etc.), hydrochloric acid, odor, etc.
- Alkyl which may be substituted for example, methyl, ethyl, propyl, isopyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl
- alkyl which may be substituted for example, methyl, ethyl, propyl, isopyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl
- cycloalkyl e.g., cyclopropyl, Shikuropuchi Le, cyclopentyl, cyclohexyl, C 3, such as heptyl cyclohexane - such as 7 cycloalkyl Le and the like;
- cycloalkenyl which may be substituted (for example, cycloalkenyl having 3 to 7 carbon atoms such as 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl, etc.) );
- Lucanoyl eg, acetyl, propionyl, butyryl, isoptyryl, etc.
- alkylsulfonyl eg, methanesulfonyl, ethanesulfonyl, etc.
- alkylsulfonyl eg, methanesulfonyl, ethanesulfonyl, etc.
- An amino group which may have one or two optionally substituted aryl (eg, phenyl, naphthyl, etc.) and the like.
- the optionally substituted acyl, and (6) the optionally substituted aryl may have a halogen (eg, fluorine, chlorine, bromine, iodine, etc.), nitro, Cyano, hydroxyl group, optionally substituted thiol group
- an optionally substituted amino group e.g., Amino, Mono C j _ 4 Arukiruamino, C -! 4 Arukiruamino, Tetorahidoropi roll, piperidines Rajin, piperidine, morpholine, thiomorpholine, pyromellitic Ichiru, such as 5 or 6 membered cyclic Amino, such as imidazole
- Rupokishiru group eg be esterified or amidated, Karupokishiru, C!
- a nitrogen-containing heterocyclic group which may contain an oxygen atom, and a nitrogen atom may be quaternized or oxidized, (3) optionally substituted amidino group or (4) substituted Is preferably a guanidino group;
- R 2 may be substituted; an amino group in which a nitrogen atom may be quaternized ammonium; an amino group which may be substituted; and sulfur as a ring-constituting atom
- An amino group which may contain an atom or an oxygen atom, a nitrogen-containing heterocyclic group which may be oxidized at a nitrogen atom, etc., is more preferably an amino group which may be substituted, Ku, such as sulfur or oxygen atom nitrogen-containing heterocyclic group which may contain as a ring-constituting atom is particularly preferred arbitrariness.
- R 2 is a group represented by the formula —NRR ”or —.N + RR′R” (wherein, R, R ′ and R ′′ are each an optionally substituted aliphatic hydrocarbon group (aliphatic A chain hydrocarbon group and an aliphatic cyclic hydrocarbon group) or an optionally substituted alicyclic (non-aromatic) complex ring group), which may be substituted, and in which a nitrogen atom is oxidized.
- R, R ′ and R ′′ are each an optionally substituted aliphatic hydrocarbon group (aliphatic A chain hydrocarbon group and an aliphatic cyclic hydrocarbon group) or an optionally substituted alicyclic (non-aromatic) complex ring group), which may be substituted, and in which a nitrogen atom is oxidized.
- a nitrogen-containing aromatic heterocyclic group which may be further preferred.
- the “optionally substituted aliphatic hydrocarbon group” and the “optionally substituted alicyclic heterocyclic group” represented by R, R ′ and R ′′ are the substituents R 2
- the optionally substituted aliphatic hydrocarbon group e.g., each optionally substituted alkyl group
- exemplified as the substituent that the optionally substituted amino group may have , Cycloalkyl, alkenyl, cycloalkenyl, etc.
- “optionally substituted alicyclic heterocyclic group eg, optionally substituted 5- or 6-membered non-aromatic heterocycle, etc.)” Things.
- R and R ' are preferably an optionally substituted chain hydrocarbon group (eg, alkyl or alkenyl each of which may be substituted), and may be optionally substituted Ci-- 6 alkyl groups are more preferable, and a methyl group which may be substituted is Especially preferred.
- R and R ' are preferably an optionally substituted chain hydrocarbon group (eg, alkyl or alkenyl each of which may be substituted), and may be optionally substituted Ci-- 6 alkyl groups are more preferable, and a methyl group which may be substituted is Especially preferred.
- the R " (preferably, optionally substituted C 3 _ 8 cycloalkyl group optionally; more preferably cyclohexyl which may consequent opening substituted) optionally substituted alicyclic hydrocarbon group, or
- An optionally substituted alicyclic heterocyclic group (preferably, an optionally substituted saturated alicyclic heterocyclic group (preferably a 6-membered ring group); more preferably, an optionally substituted tetrahydro Viranyl, optionally substituted tetrahydrothiopyranyl or optionally substituted piperidyl; particularly preferred is optionally substituted (tetrahydroviranyl).
- Preferable examples of the salt with an organic base include, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, ⁇ '-dibenzylethylenediamine. And salts with amines.
- Preferable examples of the salt with an inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like.
- the compound (I) is an isotope (eg, 3 H, 1 C, 35 S, etc. 125 I) may be labeled with a.
- the compound used in each of the following production methods may form a salt similar to the compound (I) as long as the reaction is not hindered.
- the starting compound has an amino group, a propyloxyl group, or a hydroxyl group as a substituent
- these compounds are generally used in peptide chemistry and the like.
- the protective compound may be introduced into the target compound, and the target compound can be obtained by removing the protective group as necessary after the reaction.
- substituents include a halogen atom (for example, fluorine, chlorine, bromine, iodine, etc.), C i- 6 alkyl, phenyl, and C 7 —.
- Aralkyl and nitro groups are used, and the number of substituents is about 1 to 4.
- a method for introducing and removing a protecting group a method known per se or a method analogous thereto (for example, a method described in Protective Group's' in 'organic' chemistry (JF • W.
- the method of removal includes, for example, a method of treating with acid, base, reduction, ultraviolet light, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate and the like. Used.
- Compound (I) can be produced by reacting compound (II) with compound (III) according to the following reaction.
- compound (I) is produced by reacting carboxylic acid derivative (II) with amamine derivative (III).
- the condensation reaction between the compound (II) and the compound (III) is carried out by a usual peptide synthesis means.
- the means for peptide synthesis may be in accordance with any known method, for example, M. Bodansky and And MA Ondetti, Peptide Synthesis, Interscience, New York, 1966; FM Finn and K. Hofmann, The Proteins, Volume 2, H. Nenrath, RL Hill Editing, Academic Press Inc., New York, 1976; Nobuo Izumiya et al., "Basics and Experiments in Peptide Synthesis", Maruzen Co., Ltd., 1998, etc.
- Chloride method acid anhydride method, mixed anhydride method, DCC method, active ester method, method using Woodward reagent K, porponyldiimidazole method, redox method, DCCZHONB method, etc.
- Method a method using getyl cyanophosphate (DEPC), and the like.
- acid halides eg, acid chloride, acid bromide, etc.
- acid azides eg, acid anhydrides, mixed acid anhydrides (eg, mono- 6 alkyl carbonate mixed acid anhydrides (eg, free acid Mixed anhydrides of acids with monomethylcarbonate, monoethylcarbonate, monoisopropylcarbonate, monoisobutylcarbonate, monotert-butylcarbonate, monobenzylcarbonate, mono (p-nitrobenzyl) carbonate, monoallylcarbonate, etc.), Ci — 6 aliphatic carboxylic acid mixed anhydrides (eg free acid and acetic acid, trichloroacetic acid, cyanoacetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, pivalic acid, trifluoroacetic acid, trichloroacetic acid acetic acid, mixed acid anhydride and the like Aseto acetate
- This condensation reaction can be performed in a solvent.
- the solvent include anhydrous or water-containing N, N-dimethylformamide, dimethylsulfoxide, pyridine, chloroform, dichloromethane, tetrahydrofuran, dioxane, acetonitrile, or an appropriate mixture thereof.
- the reaction temperature is usually about ⁇ 20 ° C. to about 50 ° C., preferably about ⁇ 10 ° C. to about 30 ° C.
- the reaction time is about 1 to about 100 hours, preferably about 2 to about 40 hours.
- the compound (I) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like.
- R 2 a 'represented by the compound (1-1) is, for example, a secondary amine residue: the compound (I-11) and an aldehyde compound are treated with sodium triacetoxyborohydride, sodium borohydride, or
- the tertiary compound (I,) can be produced by reacting in the presence of a reducing amino reagent such as sodium borohydride. In this reductive amination reaction, it is desirable to change the anti-reaction conditions depending on the reagent used.
- an inert solvent such as dichloromethane, chloroform, 1,2- Dichloroethane, tetrahydrofuran (THF), dimethyl ether, dioxane, acetonitrile, dimethylformamide (DMF), etc., or a mixed solvent thereof.
- THF tetrahydrofuran
- DMF dimethylformamide
- Reaction is usually about 0 ° C to about 8
- R 2 a ′ represented by the compound (1-1) is, for example, a sulfide residue or a tertiary amine residue, or when Z 2 is, for example, a sulfide residue
- the compound (I-11) Is reacted with an oxidizing agent such as m-chloroperbenzoic acid, perbenzoic acid, paranitroperbenzoic acid, magnesium monoperoxyphthalate, peracetic acid, hydrogen peroxide, sodium periodate, periodic acid lime, etc.
- an oxidizing agent such as m-chloroperbenzoic acid, perbenzoic acid, paranitroperbenzoic acid, magnesium monoperoxyphthalate, peracetic acid, hydrogen peroxide, sodium periodate, periodic acid lime, etc.
- reaction conditions depending on the oxidizing agent to be used.
- an inert solvent such as dichloromethane, chloroform, 1,2-dichloroethane, and getyl are used.
- the reaction can be performed in ether, tetrahydrofuran, acetone, ethyl acetate, or a mixed solvent thereof.
- the oxidizing agent is used in an amount of about 1 to 3 molar equivalents per 1 mole of the compound (I-1).
- the reaction is usually carried out at a temperature in the range of about 78 to about 80 (preferably about 50 ° C to 25 ° C) for about 1 hour to about 40 hours.
- a quaternized compound (I ') can be produced by reacting the compound (IV) with a tertiary amine. This reaction is carried out in an inert solvent such as toluene, benzene
- the compound having an ether bond ( ⁇ ,) is an etherification reaction of the compound (V) with a reactive compound such as a halide (chloride, bromide, iodide, etc.) compound, a tositol compound, a mesylate compound, or the like. Can also be manufactured.
- the reactive compound is generally used in an amount of about 1 to 2 moles per 1 mole of the compound (V). This reaction is carried out, if necessary, in an amount of about equimolar to about 3 moles of triethylamine, diisopropylethylamine, pyridine, lithium hydride, sodium hydride, sodium hydroxide, potassium hydroxide, sodium methoxide.
- This substitution reaction is carried out in an inert solvent such as methanol, ethanol, propanol, isopropanol, n -butanol, tetrahydrofuran, Getyl ether, dimethoxyethane, 1,4-dioxane, toluene, benzene, xylene, dichloromethane, chloroform, 1,2-dichloroethane, dimethylformamide (DMF), dimethylsulfoxide (DMSO), pyridine, etc.
- the reaction is carried out at a temperature in the range of about 0 ° C to 150 ° C for about 1 hour to about 50 hours.
- This reaction is preferably performed in an atmosphere of an inert gas (eg, nitrogen, argon, etc.).
- reaction By adding a salt, the reaction can proceed smoothly.
- This substitution reaction is carried out using an inert solvent such as methanol, ethanol, propanol, isopropanol, n-butanol, tetrahydrofuran, getyl ether, dimethoxyethane, 1,4-dioxane, toluene, benzene, xylene.
- the reaction can be performed in dichloromethane, dichloromethane, chloroform, 1,2-dichloroethane, dimethylformamide (DMF), dimethylsulfoxide (DMSO), pyridine, etc., or a mixed solvent thereof.
- the reaction is carried out at a temperature of about 0 "C to 150 ° C for about 1 hour to about 50 hours.
- This reaction is preferably carried out in an atmosphere of an inert gas (eg, nitrogen, argon, etc.).
- (II-1) used as a starting material may be prepared by a known method (for example, a method described in JP-A-8-73346 and JP-A-2001-58988), or The compound can be produced by a method according to the method, for example, the method represented by the reaction formula I, the method shown in the following reference example, or a method according to the method.
- X 1 is a leaving group [halogen atom (chlorine, bromine, etc. ® ⁇ iodine), methanesulfonyloxy O carboxymethyl, triflumizole Ruo Lome drawers Ruhoniru, Benzenesulfonyloxy, toluenesulfonyloxy, etc.], and Y ′ ′ represents a divalent group containing no unsaturated bond, in which the ring containing Y ′′ forms a 6 to 10-membered ring, and other symbols Is as defined above. ].
- the reduction reaction of compound (XII) can be performed by a method known per se. For example, reduction with a metal, reduction with a metal hydride, reduction with a metal hydride complex, reduction with dipolane and substituted porane, catalytic hydrogenation, and the like are used. That is, this reaction is carried out by treating compound (XI I) with a reducing agent.
- the reducing agent include metals such as reduced iron and zinc powder, alkali metal borohydrides (eg, sodium borohydride, lithium borohydride, etc.), metal hydride complex compounds such as lithium aluminum hydride, and sodium hydride.
- the compound (I-1) thus obtained can be isolated and purified by known separation and purification means such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like.
- the compound represented by the formula (I) of the present invention including the compound (la), the compound (I-11), the compound (I'), the compound (I ") and the compound ( ⁇ ''), Salts (hereinafter, when abbreviated to a compound represented by the formula (I), include the salt and the compound represented by the formula (I) and the salt thereof) may be used alone or pharmaceutically acceptable. It can be administered orally or parenterally as a pharmaceutical composition combined with a carrier, for example, a solid preparation such as tablets, capsules, granules, powders and the like; or a liquid preparation such as syrups and injections.
- a carrier for example, a solid preparation such as tablets, capsules, granules, powders and the like; or a liquid preparation such as syrups and injections.
- Parenteral administration forms include injections, infusions, suppositories, vaginal suppositories, etc., and vaginal suppositories are particularly useful for preventing HIV infection.
- various organic or inorganic carriers commonly used as a drug substance can be used, such as excipients, lubricants, binders, and disintegrants in solid preparations; solvents in liquid preparations; Formulated as solubilizers, suspending agents, tonicity agents, buffers, soothing agents and the like. If necessary, pharmaceutical additives such as preservatives, antioxidants, coloring agents and sweeteners can also be used.
- excipients include lactose, sucrose, D-mannitol, starch, crystalline cellulose, light caffeic anhydride and the like.
- the lubricant include, for example, magnesium stearate, calcium stearate, talc, colloid silica and the like.
- Preferred examples of the binder include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like.
- Suitable examples of disintegrants include, for example, starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethylsuccinate and the like.
- Suitable examples of the solvent include, for example, water for injection, alcohol Propylene glycol, macrogol, sesame oil, corn oil and the like.
- solubilizers include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate And so on.
- the suspending agent include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalconium chloride, benzethonium chloride, and glycerin monostearate;
- surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalconium chloride, benzethonium chloride, and glycerin monostearate
- hydrophilic polymers such as alcohol, polyvinylpyrrolidone, sodium carboxymethyl cellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose.
- Preferred examples of the tonicity agent include sodium chloride, glycerin, D-mannitol and the like.
- Preferred examples of the buffer include buffers such as phosphate, acetate, carbonate, and citrate.
- Preferable examples of the soothing agent include, for example, benzyl alcohol.
- Preferred examples of the preservative include, for example, paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- Suitable examples of the antioxidant include, for example, sulfite, ascorbic acid and the like.
- the compound of the present invention represented by the formula (I) or a salt thereof has excellent CCR antagonism, particularly CCR 5 and / or CCR 2 antagonism, especially strong CCR 5 antagonism. It can be used to prevent and treat HIV infections, such as AIDS, and to prevent and treat various other diseases. Further, the compound represented by the formula (I) of the present invention or a salt thereof has low toxicity and can be used safely.
- the pharmaceutical composition containing the compound represented by the formula (I) or a salt thereof of the present invention can be used as a CCR5 antagonist, for example, an agent for preventing or treating AIDS and an agent for suppressing the progression of AIDS pathology.
- the pharmaceutical composition containing the compound represented by the formula (I) or a salt thereof of the present invention can be used for graft-versus-host disease (GVHD; Graft Versus Hospital Disorder). Prevention of rejection and / or rejection ⁇ Can be used as a therapeutic agent.
- GVHD graft-versus-host disease
- Prevention of rejection and / or rejection ⁇ Can be used as a therapeutic agent.
- Diseases targeted by the preventive and therapeutic agents of the present invention include, for example, graft rejection (rejection after transplantation, erythrocytosis after transplantation, hypertension, organ damage, vascular hypertrophy, graft-versus-host disease, etc.) , Arthritis bone diseases such as meningitis, rheumatoid arthritis, osteoarthritis, rheumatoid myelitis, osteoporosis, abnormal proliferation of cells, bone fractures, refractures, osteomalacia, bone Petiet's disease, rigidity Myelitis, osteoarthritis of the knee, and joint tissue destruction in similar diseases, etc.), autoimmune diseases (collagenous disease, systemic lupus erythematosus, scleroderma, polyarteritis, myasthenia gravis, multiple sclerosis) , Etc.), allergic diseases (allergic rhinitis, conjunctivitis, gastrointestinal allergy, hay fever, anaphylaxis,
- the pharmaceutical composition of the present invention containing the compound represented by the formula (I) or a salt thereof varies depending on the kind of the target disease, but may be used in combination with other drugs.
- other drugs include, for example, HDL-increasing drugs (squalene synthase inhibitors, CETP inhibitors, LPL activators, etc.), HIV infectious disease preventive and therapeutic agents [zidovudine, zidanosine (dicanosine) ), Zalcitahin alci tabine), lamivudine (lamivudine), stavudine (stavudine), aba virvir (abacavir), adefovir (adefovir), 7 defovir dipivoxil (adefovir dipivoxil), fozivudine tidexil (foziv, etc.)
- Non-nucleic acid reverse transcriptase inhibitors such as nevirapine, nevirapine, delavirdine, ef
- Atopic dermatitis drug [sodium cromoglycate, etc.] , Allergic rhinitis treatment [sodium cromoglycate, chlorpheniramine maleate, alimemazine tartrate, clemastine fumarate, homochlorcyclidine hydrochloride, terfenadine, mequitazine, etc.], imidenem-cilastatin sodium, endotoxin antagonist or antibody
- Oxidosqualene-lanostero-recyclase [eg decalin derivatives, azaderic phosphorus derivatives and indane derivatives]
- calcium antagonists such as diltiazem
- glycerol eglycerol
- cholinesterase inhibitors eg, alicebut (donebezil), etc.
- Cholesterol Compounds that inhibit absorption eg, sitosterol and neomycin
- Compounds that inhibit cholesterol biosynthesis eg, HMG-CoA reducta
- Antiplatelet and anticoagulants, valpital anticonvulsants or anesthetics phenobarbital, 'mehobarbital, metalpital, etc.
- drugs for Parkinson's disease eg L Pedipa drugs
- histamine receptor blockers cimetidine, famotidine, etc.
- hydantoin anticonvulsants phenytoin, mephenitoin, etotoin, etc.
- piroxicam piroxicam
- fibrates [eg, clofibrate, benzafibrate] , Gemfiprodil, etc.)
- prostaglandins megestrol acetate, stomach, duodenal ulcer remedies therapeutic drugs: antacids [eg, histamine H2 antagonists (cimetidine, etc.), proton pump inhibitors (lansoprazole , Etc.), inflammatory mediator inhibitor, coronary vasodilators: nifedipine, dil
- Infectious disease therapeutics [eg, antibiotic preparations (cefatiam hydrochloride, cefozopran hydrochloride, Ampicillin, etc.), chemotherapeutic agents (sulfa drugs, synthetic antibacterial agents, anti-will Medicines), biological products (vaccines, blood products such as immunoglobulins), etc.], therapeutic agents for liver diseases: glycyrrhizin preparations [eg, strong minophagen, etc.], liver hydrolyzate, SH compounds [eg, daltathione etc.], special amino acid formulations [eg, Aminoreban, etc.], phospholipids [example, Po Lin phosphatidyl choline, etc.], vitamins [eg, vitamin B, B 2, B 6, B!
- Bone disease drugs calcium preparations (eg, calcium carbonate, etc.), calcitonin preparations, active vitamins! 3 preparations (eg, alfacalcidol (alfalol, etc.), calcitriol (mouth cartrol), etc.), sex hormones (eg, estrogens, .estrandiol, etc.), hormone preparations [eg, conjugated estrogens (premarin, etc.) ), etc.], etc.
- Ivry flavone formulations (Osten), vitamin K 2, vitamin kappa 2 formulation example, Menatetore non (lazy one), etc.], etc.
- Bi evening Min D 3 derivatives such as hydroxy cholecalciferol Schiff Errol, 5, 6 Toransuerugo Vitamin D 2 derivatives such as calciferol, etc.
- disease-modifying antirheumatic drugs and immunosuppressive drugs eg, methotrexate, leflunomide, prograf, sulfasalazine, D-penicillamine, oral gold preparations
- 'pressor drugs dopamine , Dopamine, denopamine, digitoxin, digoxin, methyldigoxin, lanatoside, G—strophanthin, etc.]
- cardioprotective drugs include cardiac ATP— K openers, Na— ⁇ exchange inhibitors, endothelin antagonists, ⁇ rotincin antagonists, etc., treatments for heart failure [inotropic drugs (eg, digitoxin, digoxin, methyldigoxin, lanatoside C, prossilalidine, etc.), / 3 stimulants (eg, epin
- Nerve Nutrition factors for example, monoclonal antibodies (eg, anti-TNF- ⁇ antibody, anti-IL-12 antibody, anti-IL16 antibody, anti-ICAM-I antibody, anti-CD 4 antibodies), soluble receptors (eg, soluble TNF- ⁇ receptor, etc.), protein ligands (IL-I receptor, etc.), bile acid binding resins [eg, cholestyramine, Central nervous system drugs such as colestipol, etc.], biliary tract treatment drugs: bile drugs [eg, dehydrocholic acid, etc.], sedatives [eg, magnesium sulfate, etc.]: anxiolytics, hypnotics, anesthetics , Antispasmodics, autonomic nervous drugs, anti-parkinson drugs and other psychiatric drugs, etc.
- monoclonal antibodies eg, anti-TNF- ⁇ antibody, anti-IL-12 antibody, anti-IL16 antibody, anti-ICAM-I antibody, anti-CD 4 antibodies
- Isodilic acid, etc. brain function stimulants (eg, idebenone, vinpocetine, etc.), urinary and male genital diseases: [eg, prostatic hypertrophy treatments (musculosyn hydrochloride, prazosin hydrochloride, chrome madinone acetate) ), Prostate cancer treatments (leuprorelin acetate, goserelin acetate, chlormadinone acetate, etc.)], non-steroid anti-inflammatory drugs [acetaminophen, phenacetin, ethenzamide, sulpyrine, antipyrine, migrenine, aspirin, mephenamic acid, Flufenamic acid, diclofenac sodium, loxoprofen sodium, fenilbutazone, indomethacin, ibuprofen, ketoprofen, ketoprofen, naproxen, oxaprozin, flurbiprofen, fenbufen, bla
- the dosage for a particular patient will depend on age, weight, general health, gender, diet, time of administration, mode of administration, rate of excretion, and the extent of the condition the patient is treating at the time, or It is determined in consideration of other factors.
- the dosage of the above pharmaceutical composition used as an AIDS prophylactic or therapeutic agent or an AIDS disease progression inhibitor varies depending on the patient's condition, body weight, and administration method.
- the active ingredient per person [compound represented by formula (I)] is about 5 to 1,000 mg, preferably about 10 to 60 mg, more preferably about 10 to 300 mg, It is preferably about 15 to 15 Omg, and is administered once or twice or three times a day.
- the above pharmaceutical composition When the above pharmaceutical composition is used as a preventive / therapeutic agent for graft versus host disease and Z or rejection in transplanting organs such as heart, kidney, liver, bone marrow, etc. It is administered continuously even after transplantation.
- the daily dose of the pharmaceutical composition of the present invention varies depending on the condition and weight of the patient and the method of administration.
- the active ingredient per adult (body weight 5 O kg) is expressed by the formula (I). Is about 5 to 100 Omg, preferably about 10 to 600 mg, more preferably about 10 to 30 Omg, particularly preferably about 15 to 15 Omg, It is administered once or twice or three times a day.
- the dose of the other drug is appropriately selected, for example, in a range of about 1/200 to 1/2 or more and about 2 to 3 times or less of the usual dose. You.
- the dose of each drug is adjusted appropriately, but generally, The dose at the time of single administration of each drug is used.
- the preventive agent for HIV infection of the present invention is administered separately from blood or blood products to be transfused at the time of blood transfusion or use of blood products, it is desirable to administer the blood transfusion or blood products one hour before or simultaneously with the use of blood products, and more preferably It is preferable to continue administration once or three times a day for 4 weeks.
- a 4N aqueous sodium hydroxide solution (6.8 ml) was added to N-propyl-2-piridone (1.92 g), and the mixture was refluxed at 115T for 5 hours. After neutralization by adding concentrated hydrochloric acid (2.27 ml) at 0 ° C, sodium carbonate (2.88 g), water (11.5 ml) and DMSMS (18.2 ml) were added. added. After heating to 90, a solution of 5-bromo-12-cloniconicotine aldehyde (1.5 g) in DMS O (23 ml) was added dropwise, and the mixture was stirred as it was for 2 hours.
- the CCR5 gene was cloned from human spleen cDNA by the PCR method.
- 0.5 ng of spleen cDNA was type III, and reported by Samson et al. (Biochemistry 35 (1 1), 33 6 2-3 3 6 7 (1 9 9 6 )) Primer set prepared with reference to the CCR5 gene base sequence.
- SEQ ID NO: 2 described in Experimental Example (1) of WO99 / 3210 [sequence length: 34; sequence type: nucleic acid; number of chains: single-stranded; topology: linear Form; sequence type: other nucleic acid synthetic DNA]
- the plasmid obtained above was digested with restriction enzymes Xbal (Takara Shuzo) and BamHI (Takara Shuzo), and then agarose gel electrophoresis was performed to recover about 1. Okb DNA fragment.
- the DNA fragment and the expression plasmid pcDNA3.1 (Funakoshi) for animal cells digested with Xbal and BamHI are mixed, ligated with DNA Ligation Kit Ver. 2 (Takara Shuzo), and the E. coli JM109 competent cells ( (Takara Shuzo) was transformed to obtain plasmid pCKR5.
- dienetisin (Lifetech Oriental) to 500 g / ml 1 0% was added to a ⁇ sheet suspended in ham F 1 2 medium containing calf serum, 1 0 4 cells Zml become so diluted to 96 Uerupure - seeded on preparative (Becton Dickinson), A geneticin resistant strain was obtained.
- the obtained dineticin-resistant strain was cultured in a 96-L plate (Becton Dickinson), and CCR5-expressing cells were selected from the resistant strains. That is, Atseva with 200pM [1 2 5 1] -RANTE S (Amersham) added as a ligand.
- the binding reaction was carried out at room temperature for 40 minutes in a buffer (ham F12 medium containing 0.5% BSA, 2 OmM HE PES (Wako Pure Chemicals, pH 7.2)), and washed with ice-cooled PBS. 1 M Na ⁇ H was added at 50 a1 / ⁇ , and the mixture was stirred. The radioactivity was measured with an alpha counter to select cells to which the ligand was specifically bound, and the CCR5 / CHO strain.
- the compound represented by the formula (I) of the present invention or a salt thereof has a strong CCR5 antagonism and has an improved solubility in water, so that various HIV infections in humans such as AIDS It can be used advantageously for prevention as well as treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/544,435 US7288654B2 (en) | 2003-02-07 | 2004-02-05 | Fused-ring pyridine derivative, process for producing the same, and use |
EP04708468A EP1593680A4 (en) | 2003-02-07 | 2004-02-05 | PYRIDINE DERIVATIVES WITH CONDENSED RING, PROCESS FOR THEIR PREPARATION AND USE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-031036 | 2003-02-07 | ||
JP2003031036 | 2003-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004069833A1 true WO2004069833A1 (ja) | 2004-08-19 |
Family
ID=32844285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/001169 WO2004069833A1 (ja) | 2003-02-07 | 2004-02-05 | 縮環ピリジン誘導体、その製造法および用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7288654B2 (ja) |
EP (1) | EP1593680A4 (ja) |
WO (1) | WO2004069833A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
WO2008099278A2 (en) * | 2007-02-15 | 2008-08-21 | Pfizer Limited | Pharmaceutical compositions and methods for ccr5 antagonists |
EP2720754B1 (en) | 2011-06-19 | 2016-10-19 | New York University | Leukotoxin e/d as a new anti-inflammatory agent and microbicide |
LT3403669T (lt) | 2011-06-19 | 2020-10-12 | New York University | Staphylococcus aureus infekcijų ir giminingų būklių gydymo bei prevencijos būdai |
FR3100715B1 (fr) * | 2019-09-12 | 2023-09-29 | Francais Du Sang Ets | Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037455A1 (en) * | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
WO2000076993A1 (fr) * | 1999-06-16 | 2000-12-21 | Takeda Chemical Industries, Ltd. | Derives de benzazepine, procede de preparation de ces derives et utilisation |
WO2001041808A1 (fr) * | 1999-12-10 | 2001-06-14 | Takeda Chemical Industries, Ltd. | Compositions medicinales a usage par voie orale |
JP2003119191A (ja) * | 2001-08-08 | 2003-04-23 | Takeda Chem Ind Ltd | ベンゾアゼピン誘導体、その製造法および用途 |
JP2003335776A (ja) * | 2001-08-08 | 2003-11-28 | Takeda Chem Ind Ltd | 二環性化合物、その製造法および用途 |
JP2004002402A (ja) * | 2002-04-24 | 2004-01-08 | Takeda Chem Ind Ltd | Ccr拮抗作用を有する化合物の用途 |
JP2004043432A (ja) * | 2002-04-19 | 2004-02-12 | Takeda Chem Ind Ltd | Hiv感染予防剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2191980A1 (en) | 1994-07-04 | 1996-01-18 | Takashi Sohda | Phosphonic acid compounds, their production and use |
WO1997039002A1 (en) | 1996-04-12 | 1997-10-23 | Takeda Chemical Industries, Ltd. | Production of 7-aminocephalosporanic acid derivative |
KR20010032841A (ko) * | 1997-12-19 | 2001-04-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 아닐리드 유도체를 함유하는 ccr5 길항용 약학 조성물 |
ATE356813T1 (de) | 1997-12-19 | 2007-04-15 | Takeda Pharmaceutical | Anilidderivate, deren herstellung und verwendung |
US6096780A (en) | 1998-08-20 | 2000-08-01 | Takeda Chemical Industries, Ltd. | Quaternary ammonium salts and their use |
AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
-
2004
- 2004-02-05 EP EP04708468A patent/EP1593680A4/en not_active Withdrawn
- 2004-02-05 WO PCT/JP2004/001169 patent/WO2004069833A1/ja not_active Application Discontinuation
- 2004-02-05 US US10/544,435 patent/US7288654B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037455A1 (en) * | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
WO2000076993A1 (fr) * | 1999-06-16 | 2000-12-21 | Takeda Chemical Industries, Ltd. | Derives de benzazepine, procede de preparation de ces derives et utilisation |
WO2001041808A1 (fr) * | 1999-12-10 | 2001-06-14 | Takeda Chemical Industries, Ltd. | Compositions medicinales a usage par voie orale |
JP2003119191A (ja) * | 2001-08-08 | 2003-04-23 | Takeda Chem Ind Ltd | ベンゾアゼピン誘導体、その製造法および用途 |
JP2003335776A (ja) * | 2001-08-08 | 2003-11-28 | Takeda Chem Ind Ltd | 二環性化合物、その製造法および用途 |
JP2004043432A (ja) * | 2002-04-19 | 2004-02-12 | Takeda Chem Ind Ltd | Hiv感染予防剤 |
JP2004002402A (ja) * | 2002-04-24 | 2004-01-08 | Takeda Chem Ind Ltd | Ccr拮抗作用を有する化合物の用途 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1593680A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
Also Published As
Publication number | Publication date |
---|---|
EP1593680A4 (en) | 2008-05-07 |
EP1593680A1 (en) | 2005-11-09 |
US20060100197A1 (en) | 2006-05-11 |
US7288654B2 (en) | 2007-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4316203B2 (ja) | 二環性化合物、その製造法および用途 | |
US10329297B2 (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
US7262185B2 (en) | Benzazepine derivative, process for producing the same, and use | |
WO2017038909A1 (en) | Heterocyclic compounds | |
TWI723511B (zh) | 一種高活性sting蛋白激動劑化合物 | |
BR112016010041A2 (pt) | composto, medicamento, e, uso do composto ou sal | |
WO2006085685A1 (ja) | ピラゾール化合物 | |
CA2933466A1 (en) | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors | |
KR20140062480A (ko) | 핵 수송 조절인자 및 이의 용도 | |
TW200922588A (en) | Pyrimidyl indoline compounds | |
AU2020204341B2 (en) | Naphthyridinone derivatives and their use in the treatment of arrhythmia | |
CA3216163A1 (en) | Carboxy-benzimidazole glp-1r modulating compounds | |
WO2003090748A1 (fr) | Utilisation de composes a antagonisme anti-ccr | |
EA031105B1 (ru) | Ингибиторы альдостеронсинтазы | |
WO2004069834A1 (ja) | 三環性化合物、その製造方法および用途 | |
WO2004069808A1 (ja) | アクリルアミド誘導体、その製造法および用途 | |
WO2004069833A1 (ja) | 縮環ピリジン誘導体、その製造法および用途 | |
JP2004525132A (ja) | オキシトシン調節活性を有するピロリジンエステル誘導体 | |
JP2003119191A (ja) | ベンゾアゼピン誘導体、その製造法および用途 | |
JP2004256531A (ja) | 三環性化合物、その製造法および用途 | |
WO2006115285A1 (ja) | 医薬組成物 | |
WO2004026833A1 (ja) | 環状アミン化合物、その製造法および用途 | |
JP2004256530A (ja) | アクリルアミド誘導体、その製造法および用途 | |
JP2004256529A (ja) | 縮環ピリジン誘導体、その製造法および用途 | |
JP2001058992A (ja) | ベンゾアゼピン誘導体、その製造法および用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004708468 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006100197 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10544435 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004708468 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10544435 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004708468 Country of ref document: EP |